Welcome to the Medical Faculty of the University of Bonn

Das Projekt „Bone2Gene“ von Forschenden der Universität Bonn und des Universitätsklinikums Bonn (UKB) erhält eine Förderung des Programms GO-Bio initial vom Bundesministerium für Bildung und Forschung in Höhe von 1.000.000 Euro. Damit geht das Team nun in die sogenannte Machbarkeitsphase über und bereitet die Vermarktung seines Produktes vor. Zuvor hatte das Projekt bereits eine erste Förderung für die Sondierungsphase erhalten und die Marktfähigkeit des Produktes getestet. „Bone2Gene“ setzt Künstliche Intelligenz ein, um die Erkennung und Diagnose von genetischen Knochenerkrankungen, sogenannten Skelettdysplasien, zu vereinfachen.

Artificial intelligence (AI) and above all large language models (LLMs), which also form the basis for ChatGPT, are increasingly in demand in hospitals. However, patient data must always be protected. Researchers at the University Hospital Bonn (UKB) and the University of Bonn have now been able to show that local LLMs can help structure radiological findings in a privacy-safe manner, with all data remaining at the hospital. They compared various LLMs on public reports without data protection and on data-protected reports. Commercial models that require data transfer to external servers showed no advantage over local, data protection-compliant models. The results have now been published in the journal "Radiology".

Asthma, atopic dermatitis or Hashimoto's thyroiditis as concomitant diseases are risk factors for clinical features associated with a poor prognosis in circular hair loss, also known as alopecia areata (AA). In patients with three atopic diseases, namely atopic dermatitis, asthma and rhinitis, the average age of onset of AA is about ten years earlier than in patients without chronic inflammatory comorbidities. This has now been established by researchers from the University Hospital Bonn (UKB) and the University of Bonn in a large cohort study of affected patients. Their results have now been published in the journal "Allergy".

A deficiency in blood plasma coagulation factor XIII leads to a disruption in the cross-linking of fibrin, the "glue" in blood coagulation. The enzyme therefore plays an essential role in blood clotting. Researchers at the University Hospital Bonn (UKB) and the University of Bonn, together with Thermo Fisher Scientific in the Netherlands, deciphered the previously unknown structure of the Factor XIII complex using cryo-electron microscopy (cryo-EM), even at the atomic level. This enabled them to visualize the effects of disease-causing, clinically relevant factor XIII mutations in the structure of the coagulation complex. Their results have now been published in the print edition of the journal “Blood”.